Majority of Women Prefer Non-Invasive Testing for Trisomy 21

This article originally appeared here.
Share this content:
Majority of Women Prefer Non-Invasive Testing for Trisomy 21
Majority of Women Prefer Non-Invasive Testing for Trisomy 21

FRIDAY, Dec. 15, 2017 (HealthDay News) -- The majority of both high-risk and intermediate-risk women prefer a non-invasive cell-free prenatal DNA screening (NIPT) as a secondary screening test for trisomy 21, according to a study published online Nov. 10 in BJOG: An International Journal of Obstetrics and Gynaecology.

Yvonne Kwun Yue Cheng, M.B.Ch.B., from The Chinese University of Hong Kong, and colleagues examined preference for follow-up testing in women who were screened as high or intermediate risk in first- or second-trimester Down syndrome screening. Testing options included either an invasive test plus chromosomal microarray to obtain more detailed fetal genetic information or a NIPT to detect trisomies 13, 18, and 21 to avoid procedure-related miscarriage; the participants could also decline further testing.

The researchers found that of the 347 high-risk women, nearly all (99.1 percent) opted for follow-up testing, of whom 62.2 percent (216 women) chose NIPT. Of the 614 participants with intermediate risk, 82.6 percent (507 women) chose NIPT. Twenty-one percent of 34 women with nuchal translucency ≥3.5 mm opted for NIPT.

"In a setting where reporting times are similar and there is no cost difference between options, approximately 60 percent of high-risk women would opt for NIPT offering simple but limited aneuploidy assessment over a diagnostic procedure with comprehensive and more detailed assessment," the authors write.

One author disclosed a royalty-producing patent related to non-invasive prenatal diagnostics.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Lap Sleeve Gastrectomy, RYGB Equally Effective in Weight Loss

Lap Sleeve Gastrectomy, RYGB Equally Effective in Weight ...

Studies show no significant difference in BMI loss at five years between these laparoscopic procedures

ASCO: Liquid Biopsy Accurate for Detecting Colorectal Cancer

ASCO: Liquid Biopsy Accurate for Detecting Colorectal Cancer

Novel assay to detect circulating tumor cells has high sensitivity, specificity for precancerous lesions

Speech Outcomes Can Be Predicted After Cochlear Implant

Speech Outcomes Can Be Predicted After Cochlear Implant

Regions of brain that were unaffected by auditory deprivation provide most precise prediction results

is free, fast, and customized just for you!

Already a member?

Sign In Now »